Seeking Alpha

The FDA rejects Merck's (MRK) new drug application for ridaforolimus, a bone cancer treatment,...

The FDA rejects Merck's (MRK) new drug application for ridaforolimus, a bone cancer treatment, saying further trials are needed to assess the drug’s effectiveness and safety. MRK acquired the rights to the drug from Ariad Pharmaceuticals (ARIA) in 2010, which would receive $25M plus royalty payments if the drug is approved.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector